Savara Inc SVRA:NASDAQ

Last Price$1.70NASDAQ Previous Close - Last Trade as of 4:00PM ET 8/11/22

Today's Change+0.04(2.41%)
Bid (Size)$0.01 (250)
Ask (Size)$1.76 (1)
Day Low / High$1.65 - 1.71
Volume64.2 K
 

View Pharmaceuticals: Major IndustryPeer Comparison as of 08/11/2022

 

Savara Inc ( NASDAQ )

Price: $1.70
Change: +0.04 (2.41%)
Volume: 64.2 K
4:00PM ET 8/11/2022
 
 

Matinas BioPharma Holdings Inc ( NYSE MKT LLC )

Price: $0.85
Change: -0.04 (4.22%)
Volume: 10.00
8:00PM ET 8/11/2022
 
 

Assertio Holdings Inc ( NASDAQ )

Price: $3.80
Change: -0.20 (5.00%)
Volume: 211.00
4:00PM ET 8/11/2022
 
 

Fennec Pharmaceuticals Inc ( NASDAQ )

Price: $7.05
Change: -0.04 (0.49%)
Volume: 44.7 K
3:49PM ET 8/11/2022
 
 

Spectrum Pharmaceuticals Inc ( NASDAQ )

Price: $1.21
Change: +0.09 (8.04%)
Volume: 5.3 K
4:00PM ET 8/11/2022
 

Read more news Recent News

Insider Buy: Savara
1:27PM ET 6/22/2022 MT Newswires

David A Ramsay, Director, on June 17, 2022, executed a purchase for 100,000 shares in Savara (SVRA) for $138,380. Following the Form 4 filing with the SEC,...

Savara Secures Innovation Passport in UK for Molgramostim Nebulizer Solution
10:27AM ET 6/16/2022 MT Newswires

Savara (SVRA) said Thursday that UK's Medicines and Healthcare Products Regulatory Agency granted an innovation passport to its molgramostim nebulizer...

Savara Secures $26.5 Million Term Loan Agreement
10:09AM ET 4/22/2022 MT Newswires

Savara Inc. (SVRA) said Friday it has signed a term loan agreement of $26.5 million with Silicon Valley Bank to replace an existing credit facility. The...

Insider Buy: Savara
1:03PM ET 11/22/2021 MT Newswires

David A Ramsay, Director, on November 18, 2021, executed a purchase for 200,000 shares in Savara (SVRA) for $215,393. Following the Form 4 filing with the...

View all Commentary and Analysis

Biotech 101 Lecture 3: Looking At Major Biotech Catalysts
3:23PM ET 3/08/2022 Seeking Alpha

Company Profile

Business DescriptionSavara, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. The firm's lead program includes molgramostim, which is an inhaled formulation of recombinant human GM-CSF, is being developed for the treatment of autoimmune pulmonary alveolar proteinosis. The company was founded in December 1995 and is headquartered in Austin, TX. View company web site for more details
Address6836 Bee Cave Road
Austin, Texas 78746
Phone+1.512.614.1848
Number of Employees33
Recent SEC Filing08/11/202210-Q
Chairman & Chief Executive OfficerMatthew Pauls
Chief Financial Officer & SecretaryDavid L. Lowrance
Chief Medical OfficerBadrul A. Chowdhury
Senior VP-Clinical DevelopmentDhaval Desai

Company Highlights

Price Open$1.65
Previous Close$1.70
52 Week Range$1.02 - 1.91
Market Capitalization$193.9 M
Shares Outstanding114.0 M
SectorHealth Technology
IndustryPharmaceuticals: Major
Next Earnings Announcement08/11/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$0.29
Beta vs. S&P 500N/A
Revenue$0.00
Net Profit MarginN/A
Return on Equity-27.33%

Analyst Ratings as of 07/07/2022

Buy
4
Overweight
0
Hold
0
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset